Baxter

Baxter International, Inc. engages in the provision of a portfolio of essential renal and hospital products, including acute and chronic dialysis, sterile IV solutions, infusion systems and devices, parenteral nutrition therapies, premixed and oncolytic injectable, bio surgery products and anesthetics, drug reconstitution systems and pharmacy automation, software, and services. It operates through the following segment: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices and advanced equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Baxter reports robust Q4 sales, eyes growth amid operational challenges

Baxter International's Q4 2022 performance reflects strong sales growth and strategic actions to enhance agility and market responsiveness.
While facing challenges such as lower-than-expected earnings and supply chain constraints, the company is focused on cost reduction and operational improvements.
Opportunities lie in R&D investments, cost synergies from the Hillrom integration, and improving backlog and backorders, positioning Baxter for future growth.
Analysts' concerns about operating margins and financial outlook for 2023 highlight the need for continued efficiency measures and strategic planning.

Baxter beats Q1 expectations, plans spin-off for strategic clarity

Baxter's Q1 performance exceeded expectations with sales growth in key segments and adjusted EPS surpassing guidance.
The company is progressing well with its strategic initiatives, including the spin-off of Renal Care and new operating model.
Challenges in legacy businesses and soft hospital spending highlight areas for improvement, while opportunities lie in new product launches and margin enhancement strategies.
Overall, Baxter's focus on innovation, operational efficiency, and market trends positions it for long-term success and growth.

Baxter exceeds Q2 expectations, eyes growth amid strategic actions

Baxter's Q2 2023 performance showcased resilience and adaptability in a dynamic healthcare market, with strategic actions underway to drive operational efficiency and growth.
The company's focus on innovation, safety, and market responsiveness positions it well for future success, despite challenges such as pending divestitures and market uncertainties.
With a strong performance, growth opportunities in key segments, and operational improvements driving margin expansion, Baxter is navigating challenges to capitalize on future growth prospects.

Baxter beats Q3 expectations, eyes growth through strategic initiatives

Baxter's Q3 2023 performance exceeded expectations, with a focus on strategic priorities and the upcoming Kidney Care segment separation.
The company's strengths lie in maintaining market share, operational efficiencies, and maximizing shareholder value through financial analysis.
Challenges include renegotiating contracts, rising energy costs, and achieving organic growth amidst market dynamics.
Opportunities for Baxter include growth through cost improvements, margin programs, and product launches in 2024.

Baxter surpasses Q4 expectations, eyes growth amid inflation challenges

Baxter's Q4 2023 performance exceeded expectations, driven by growth in key segments and strategic initiatives, setting the stage for continued success in 2024.
Despite challenges like inflation and flat growth in certain segments, Baxter's focus on margin improvement, debt management, and growth strategies positions the company for future resilience.
With a strong outlook for 2024, Baxter aims to capitalize on opportunities for growth, margin improvement, and market expansion, supported by a solid financial foundation and strategic priorities.

Baxter surpasses Q1 expectations with focus on innovation and growth

Baxter's Q1 2024 performance exceeded expectations, driven by strong sales growth and focus on innovation, despite challenges in certain segments and geographies.
The company's strategic strengths lie in diverse growth drivers, strong segment margins, and geographic expansion successes, positioning it for continued success.
Addressing challenges in underperforming segments and markets, along with seizing opportunities for improvement and expansion, will be crucial for Baxter's future growth.
With a clear focus on innovation, margin expansion, and shareholder value maximization, Baxter aims to navigate challenges and capitalize on growth prospects for sustained success.

Baxter exceeds Q2 expectations, plans Kidney Care separation for growth

Baxter International's Q2 2024 earnings call highlighted robust performance, strategic initiatives, and a positive outlook for sales growth and earnings per share.
The company's focus on margin improvement, innovation, and operational efficiency positions it well for sustained growth and shareholder value creation.
While facing challenges in certain segments and external factors, Baxter's proactive approach and strong fundamentals offer opportunities for future expansion and success.
Investors can look forward to Baxter's continued commitment to driving growth, expanding margins, and delivering innovative healthcare solutions.

Baxter reports solid Q3 performance amidst challenges and growth opportunities

Baxter International demonstrated resilience in Q3 2024 with sales growth and earnings exceeding expectations despite challenges.
The company's focus on operational efficiency, cost containment, and strategic divestitures positions it well for future growth.
Challenges from Hurricane Helene impact and Kidney Care separation are being addressed with a clear vision for sustained performance.
Opportunities for growth and margin expansion underscore Baxter's commitment to delivering value to shareholders and patients.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Baxter International, Inc. engages in the provision of a portfolio of essential healthcare products including acute and chronic dialysis therapies, sterile intravenous (IV) solutions, infusion systems and devices, parenteral nutrition therapies, inhaled anesthetics, generic injectable pharmaceuticals, surgical hemostat and sealant products, surgical equipment, smart bed systems, patient monitoring and diagnostic technologies, and respiratory health devices. It operates through the following segments: Americas, Europe, Middle East and Africa (EMEA), Asia-Pacific (APAC), and Hillrom. The Americas, EMEA, and APAC segments offer a portfolio of essential healthcare products. The Hillrom segment provides digital and connected care solutions and collaboration tools, including smart bed systems, patient monitoring and diagnostic technologies, respiratory health devices, and equipment for the surgical space. The company was founded by Davis Baxter in 1931 and is headquartered in Deerfield, IL.

Investors need to pay close attention to Baxter International (BAX) stock based on the movements in the options market lately.

Is the Options Market Predicting a Spike in Baxter International (BAX) Stock?

DEERFIELD, Ill.--( BUSINESS WIRE )--Baxter International Inc. (NYSE: BAX), a global medtech leader, today announced it was again named to the Dow Jones Sustainability Indices (DJSI), including both DJSI World and DJSI North America. Baxter has proudly been included in the DJSI World and DJSI North America each year since they launched, in 1999 and 2005, respectively.

Baxter Named to Dow Jones Sustainability Indices for 23rd Consecutive Year

Costco

Can these stocks continue hiking their dividend payments?

2 Dividend Stocks That Have Raised Their Payouts by 80% in 5 Years

DEERFIELD, Ill.--( BUSINESS WIRE )--Baxter International Inc. (NYSE:BAX), a global leader in nutrition therapy, announces the launch of the ExactaMix Pro Automated Compounder, which is expected to be available to customers in the United States in early 2023. ExactaMix Pro will be on display at Baxter's booth #937 at the American Society of Health-System Pharmacists (ASHP) 2022 Midyear Clinical Meeting taking place Dec. 4 – Dec. 8, 2022, in Las Vegas.

Baxter Introduces ExactaMix Pro, Next-Generation Automated Nutrition Compounder, at ASHP Meeting

DEERFIELD, Ill.--( BUSINESS WIRE )--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 5th Annual Evercore ISI HealthCONx Conference on Thursday, December 1, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 1:00 p.m. Eastern Time.

Baxter to Present at the 5th Annual Evercore ISI HealthCONx Conference

Centene

CVS Health

Edwards Lifesciences

Medtronic

Zoetis

Zoetis and Medtronic are among the healthcare stocks with the most room to rise, according to Wall Street analysts' average price targets.

6 Healthcare Stocks With Room to Climb

DEERFIELD, Ill., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Baxter International Inc. (NYSE:BAX), a global innovator in kidney care, advanced scientific exchange with 14 new data presentations about the role innovation plays in increasing access to and quality of home dialysis and expanded hemodialysis (HDx) care at Kidney Week 2022, Nov. 3-6, Orlando, Florida. Key data highlighted include:

Baxter Highlights New Home Dialysis and HDx Therapy Data in 14 Clinical Presentations at Kidney Week 2022

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Spectral Medical Inc. Closes $10.8 Million Public Offering and Concurrent Private Placement

Baxter's (BAX) third-quarter results reflect the robust performance of the Medication Delivery business unit and Hilrom's businesses.

Baxter (BAX) Q3 Earnings Meet Estimates, Hilrom Adds $735 M

Start Time: 08:30 January 1, 0000 9:32 AM ET Baxter International Inc. (NYSE:BAX ) Q3 2022 Earnings Conference Call October 27, 2022, 08:30 AM ET Company Participants José Almeida - Chairman, President and CEO James Saccaro - EVP and CFO Clare Trachtman - VP, IR Conference Call Participants Travis Steed - Bank of America Securities Robbie Marcus - JPMorgan Rick Wise - Stifel Pito Chickering - Deutsche Bank Joanne Wuensch - Citigroup Joshua Jennings - Cowen and Company Operator Good morning, ladies and gentlemen, and welcome to Baxter International's Third Quarter 2022 Earnings Conference Call. Your lines will remain in a listen-only mode until the question-and-answer segment of today's call.

Baxter International Inc. (BAX) Q3 2022 Earnings Call Transcript

Baxter (BAX) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Baxter International (BAX) Q3 Earnings Match Estimates

Match Group

Olaplex Holdings

RingCentral

Block

Some of the stocks that have suffered the most this year could get hit some more as investors sell them to create tax losses.

Block, RingCentral, and Other Stocks Facing Tax-Loss Selling

Baxter Reports Third-Quarter 2022 Results

Baxter International has had a rough year or so, with shares declining far more than the market has. Some of this was justified by the company's high share price and weakening fundamentals.

Baxter International: Despite Weakening On The Bottom Line, Shares Look Attractive

Baxter's (BAX) third-quarter results are likely to reflect growth in its Medication Delivery and Advanced Surgery businesses. Hillrom's products are likely to have boosted sales.

Baxter (BAX) to Report Q3 Earnings: Is a Beat in the Cards?

Baxter (BAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Baxter International (BAX) to Report a Decline in Earnings: What to Look Out for

Investors remain optimistic about Baxter (BAX) due to its strong product portfolio.

3 Reasons to Retain Baxter (BAX) Stock in Your Portfolio

Aptiv

Coca-Cola European Partners plc

Cigna

DXC Technology

Fiserv

Global Payments

McKesson

Tenet Healthcare

US Foods Holding

Larry Robbins is the founder and CEO of Glenview Capital Management, which is a New York-based hedge fund.

These Are The Top 10 Holdings Of Larry Robbins

DEERFIELD, Ill.--(BUSINESS WIRE)--The Baxter International Foundation, the philanthropic arm of Baxter International Inc. (NYSE:BAX), announced today it will provide a combined $3 million in new racial justice grants in 2022 to multiple organizations working in the United States. The funding aligns with Baxter's ACT: Activating Change Today program, a global multidimensional and multiyear initiative to advance racial justice within the workplace and within the communities and markets the compan

The Baxter International Foundation Announces $3 Million in New Grants to Organizations Working to Advance Racial Justice

Baxter stock (NYSE: BAX) has seen a 32% fall this year, underperforming the broader S&P500 index, down 17%.

Should You Buy Baxter Stock Under $60?

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will host a conference call to discuss its third-quarter 2022 financial results on Thursday, October 27, 2022 at 7:30 a.m. Central Time. To participate in this conference call please follow this link https://conferencingportals.com/event/EmxweYhQ to pre-register for the call and receive the call information. This call is also being webcast and can be accessed through Baxter's website at www.baxter.c

Baxter to Host Third-Quarter 2022 Financial Results Conference Call for Investors

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, today reinforced its commitment to expand the pipeline of Black healthcare professionals through several programs that support Black students pursuing health and science degrees at Historically Black Colleges and Universities (HBCUs). For the 2022-2023 calendar year, Baxter is committing $200,000 to create the Baxter Nursing Scholars Award at Tennessee State University's (TSU) School of Nursing and

Baxter Expands Historically Black Colleges and Universities Partnerships, Funding Commitments to Further the Pipeline of Black Healthcare Professionals

Latest regulatory approval for Baxter's (BAX) Novum IQ SYR is expected to provide safe and accurate infusions for vulnerable patients.

Baxter (BAX) Novum IQ SYR's FDA Clearance Boosts Patient Care

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a leader in innovative technology for medication delivery, today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of its new Novum IQ syringe infusion pump (SYR) with Dose IQ Safety Software, representing Baxter's latest developments for infusion therapy. The Novum IQ SYR has the capability to fully integrate with hospital electronic medical records (EMRs) through Baxter's IQ Enterprise Connectivity Suite.

Baxter Announces U.S. FDA Clearance of Novum IQ Syringe Infusion Pump with Dose IQ Safety Software

DEERFIELD, Ill.--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX), a global medtech leader, will present at the 2022 Wells Fargo Healthcare Conference on Wednesday, September 7, 2022. Jay Saccaro, Baxter's chief financial officer, is scheduled to present at 10:25 a.m. Eastern Time. The live webcast of Baxter's presentation can be accessed at www.baxter.com and will be available for replay through February 23, 2023. About Baxter Every day, millions of patients and caregivers rely on Baxter'

News for Baxter Stock (BAX)